SCHEMBL2070675

SCHEMBL2070675

CCOC(=O)c1c(Br)ncn1-c1ccc(C)cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRG2 P18507 10/20 0.46
GABRB3 P28472 10/20 0.46
GABRA5 P31644 10/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
TP53 P04637 3/20 0.44
LMNA P02545 2/20 0.44
GABRA1 P14867 5/20 0.43
GABRA3 P34903 5/20 0.43
GABRA2 P47869 5/20 0.43
GABRA6 Q16445 5/20 0.43
POLB P06746 1/20 0.43
HCAR1 Q9BXC0 1/20 0.41
GABRB2 P47870 3/20 0.40
THRB P10828 1/20 0.39
GABRA4 P48169 2/20 0.39
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2071032 0.86 MEN1 (0.45) GABRG2GABRB3GABRA5MEN1KMT2A
SCHEMBL2069197 0.83 KDM4E (0.47) MEN1KMT2ATP53LMNAPOLB
Hydrochloric Acid SCHEMBL2070338 0.81 HCAR1 (0.44) MEN1KMT2ATP53LMNAPOLB
SCHEMBL4656876 0.80 POLB (0.43) GABRG2GABRB3GABRA5MEN1KMT2A
SCHEMBL2070757 0.75 NPSR1 (0.38) GABRG2GABRB3GABRA5MEN1KMT2A
SCHEMBL2070756 0.75 NPSR1 (0.38) GABRG2GABRB3GABRA5MEN1KMT2A
SCHEMBL2069971 0.75 LMNA (0.47) MEN1KMT2ATP53LMNATHRB
SCHEMBL2071880 0.74 CYP11B2 (0.46) GABRG2GABRB3GABRA5MEN1KMT2A
SCHEMBL21628359 0.72 KMT2A (0.46) KMT2ATP53LMNAPOLBTHRB
SCHEMBL29483962 0.72 KMT2A (0.46) KMT2ATP53LMNAPOLBTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2522670-A1 Heterocyclic CRF receptor antagonists Takeda Pharmaceutical Company Limited (JP) 2012-11-14 EP disclosed
US-7897607-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-01 US disclosed
EP-1732541-A4 CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2008-03-05 EP disclosed
US-20070179165-A1 Cyclic compounds GYORKOS ALBERT C 2007-08-02 US disclosed
EP-1732541-A2 CYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2006-12-20 EP disclosed
WO-2005099688-A2 CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179165-A1 Cyclic compounds CRHR1, CRHR2, MC2R GABRG2 795/4885GABRB3 809/4885GABRA5 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.